Stockreport

AN2 Therapeutics Provides Update on EBO-301 Phase 2/3 Study Evaluating Epetraborole for Treatment-Refractory Mycobacterium avium Complex (MAC) Lung Disease

AN2 Therapeutics, Inc.  (ANTX) 
US:NYSE Investor Relations: ir.antheminc.com
PDF EBO-301 study to be discontinued following topline results from Phase 2 part of the study in treatment-refractory patients with MAC lung diseaseAN2 plans to shift focus [Read more]